Populated franchise territories currently for sale in Aust & NZ

Learn more

TDDA logo
Health Tick Logo

1300 4 DETECTION (1300 4 33 832)

0508 DRUGTEST (0508 3784 8378)

enquire now
  • Drug Testing Services
    • Overview
    • Urine
    • Alcohol
    • Oral Fluid
    • Hair
    • Synthetic
    • Meth
    • Privacy Statement
  • Imperans
  • Background Checks
  • Training
  • Drug Policy Design
  • News
  • About
    • Who We Are
    • Our Leadership
    • Franchises
    • Privacy Statement
  • Contact

AUSTRALIA 1300 4 DETECTION (1300 4 33 832)

NEW ZEALAND 0508 DRUGTEST (0508 3784 8378)

TDDA logo
Health Tick Logo
  • Drug Testing Services
    • Overview
    • Urine
    • Alcohol
    • Oral Fluid
    • Hair
    • Synthetic
    • Meth
    • Privacy Statement
  • Imperans
  • Background Checks
  • Training
  • Drug Policy Design
  • News
  • About
    • Who We Are
    • Our Leadership
    • Franchises
    • Privacy Statement
  • Contact

Glenn Dobson on Newstalk ZB – Drive with Heather du Plessis-Allan

by Maree Boyd | May 19, 2025 | TDDA in the news

Glenn Dobson was invited to speak on radio to Heather du Plessis-Allan “NewstalkZB Drive” to discuss new TDDA New Zealand data that shows methamphetamine (meth) detection is growing and making up a disproportionate share of non-negative workplace drug test results....

TDDA continues to lead the way with drug testing innovation as featured in the DEMM Engineering & Manufacturing publication – “TDDA adds Tramadol and Fentanyl testing”

https://demm.co.nz/article/tdda-adds-tramadol-and-fentanyl-testing
COMING SOON – 2 new drug types added to TDDA drug screening devices

COMING SOON – 2 new drug types added to TDDA drug screening devices

by Maree Boyd | Feb 21, 2025 | Content by TDDA

TDDA are proud to announce the soon to be released updated TDDA branded oral fluid and urine screening devices that includes the option of 2 extra drug types “Tramadol & Fentanyl”. The development of these new screening devices is part of TDDA’s ongoing commitment...

An alert has been put out in New Zealand for a new synthetic cannabinoid being misrepresented as a benzodiazepine. This highlights the dangers of synthetic drugs being marketed as another type of drug creating the high potential of harm to users.

https://www.highalert.org.nz/alerts-and-notifications/new-synthetic-cannabinoid-misrepresented-as-a-benzodiazepine

‘Living document’: Employers urged to keep drug-testing policies updated amid shifting trends

by Maree Boyd | Nov 15, 2024 | Content by TDDA

In this insightful article, Glenn Dobson discusses the critical need for employers to regularly update their drug and alcohol policies to ensure compliance with shifting legal frameworks and emerging workplace trends. With rising concerns around THC use and opioid...
« Older Entries
Next Entries »

Recent Posts

  • Protecting the girl on the bike: Why workplace drug testing is about more than compliance
  • New Zealand – Imperans Q1 2026 Report, State of Workplace Drug Use from TDDA
  • Australia – Imperans Q1 2026 Report, State of Workplace Drug Use from TDDA
  • Australia – Imperans Q4 Report, State of Workplace Drug Use from TDDA
  • New Zealand – Imperans Q4 Report, State of Workplace Drug Use from TDDA

Recent Comments

No comments to show.
TDDA logo

Contact us

NEW ZEALAND
0508 DRUGTEST (0508 3784 8378)
AUSTRALIA
1300 4 DETECTION (1300 4 33 832)

Find your local tdda office

enquire now

© TDDA 2026 • Privacy and Data Protection Statement • Website designed by Husk
  • Follow
  • Follow